Publication | Open Access

In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure

Regenerative MedicineCell TherapyMedicineStem CellsImmunologyStem Cell ResearchVascular BiologyPhase 1AStem-cell TherapyBiomedical EngineeringMesenchymal Stem CellNeovascularizationMicrovascular DysfunctionChronic Kidney DiseaseCell TransplantationNephrologyBlood PressureInflammatory Biomarkers